DMAC (DiaMedica Therapeutics) Change In Receivables : $0.13 Mil (TTM As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is DiaMedica Therapeutics Change In Receivables?

DiaMedica Therapeutics's change in receivables for the quarter that ended in Dec. 2024 was $0.05 Mil. It means DiaMedica Therapeutics's Accounts Receivable declined by $0.05 Mil from Sep. 2024 to Dec. 2024 .

DiaMedica Therapeutics's change in receivables for the fiscal year that ended in Dec. 2024 was $0.13 Mil. It means DiaMedica Therapeutics's Accounts Receivable declined by $0.13 Mil from Dec. 2023 to Dec. 2024 .

DiaMedica Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. DiaMedica Therapeutics's liquidation value for the three months ended in Dec. 2024 was $38.52 Mil.

DiaMedica Therapeutics Change In Receivables Historical Data

The historical data trend for DiaMedica Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DiaMedica Therapeutics Change In Receivables Chart

DiaMedica Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

0.48

0.21

0.05

-0.29

0.13

DiaMedica Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-0.06	-0.03	0.01	0.10	0.05

DiaMedica Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.13 Mil.

DiaMedica Therapeutics (NAS:DMAC) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

DiaMedica Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.001	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, DiaMedica Therapeutics's accounts receivable are only considered to be worth 75% of book value:

DiaMedica Therapeutics's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	44.147	-	5.627	+	0.75 * 0.001	+	0.5 * 0
=	38.52

DiaMedica Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

DiaMedica Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305

Website

https://www.diamedica.com

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Executives

Jan Stahlberg	10 percent owner	C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Koch Thomas Von	10 percent owner	TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Scott Kellen	officer: CFO and Secretary	3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre	director	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill	10 percent owner	SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik	director	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls	director, officer: President and CEO	2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto	10 percent owner	394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke	officer: Chief Business Officer	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt	10 percent owner	C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Ab Tomenterprise	10 percent owner	C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba	director	TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz	director	MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves	officer: SVP Clinical Development Oper.	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305